Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura

Completed · Early Phase 1

Conditions studied: Nonneoplastic Condition

In brief

RATIONALE: Rituximab and prednisone may increase the number of platelets in patients with immune thrombocytopenic purpura. PURPOSE: This phase II trial is studying the side effects and how well giving rituximab together with prednisone works as first-line therapy in treating patients with immune thrombocytopenic purpura.

Key facts

Study ID

NCT00486421

Run by

Mayo Clinic

People needed

22

Starts

2007-01-01

Expected to finish

2008-11-01

Last updated by the study team

2014-10-17

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Mayo Clinic — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.